Niagen Bioscience, Inc.
NAGE
$4.78
-$0.04-0.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.95% | 36.04% | 35.89% | 29.77% | 19.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.95% | 36.04% | 35.89% | 29.77% | 19.18% |
| Cost of Revenue | 21.63% | 27.40% | 26.19% | 24.70% | 15.92% |
| Gross Profit | 35.08% | 41.47% | 42.15% | 33.01% | 21.28% |
| SG&A Expenses | 30.76% | 8.84% | 6.90% | -0.34% | -6.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.31% | 15.55% | 13.37% | 8.19% | 3.03% |
| Operating Income | 85.04% | 4,218.57% | 824.15% | 403.28% | 237.99% |
| Income Before Tax | 105.44% | 1,331.11% | 1,455.77% | 513.21% | 279.32% |
| Income Tax Expenses | 165.57% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 103.30% | 1,275.69% | 1,411.32% | 499.80% | 273.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 103.30% | 1,275.69% | 1,411.32% | 499.80% | 273.15% |
| EBIT | 85.04% | 4,218.57% | 824.15% | 403.28% | 237.99% |
| EBITDA | 76.59% | 1,458.93% | 1,354.64% | 513.99% | 286.83% |
| EPS Basic | 97.39% | 1,240.00% | 1,370.00% | 489.15% | 268.89% |
| Normalized Basic EPS | 78.06% | 1,304.13% | 1,407.08% | 500.34% | 274.33% |
| EPS Diluted | 107.90% | 2,312.24% | 997.39% | 414.77% | 241.06% |
| Normalized Diluted EPS | 74.34% | 1,241.53% | 1,328.32% | 478.31% | 265.13% |
| Average Basic Shares Outstanding | 4.28% | 3.94% | 3.00% | 1.97% | 1.26% |
| Average Diluted Shares Outstanding | 10.04% | 11.22% | 9.29% | 5.95% | 3.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |